| Literature DB >> 9468021 |
U P Schwarz1, P Plascjak, M P Beitzel, O A Gansow, W C Eckelman, T A Waldmann.
Abstract
These studies describe the production and purification of 211At as well as the procedure for labeling humanized anti-Tac, the antibody to the alpha-chain of the IL-2 receptor (IL-2R alpha), which has been shown to be a useful target for immunotherapy. The optimized protocol combines the advantages of the two-stage dry distillation procedure with the astatination of trialkylstannyl substances as labeling compounds for proteins. The 211At was produced by bombarding either an external or a recently developed disposable internal bismuth target with alpha-particles from a Cyclotron Corporation CS-30 cyclotron. The 211At was found to contain less than 0.01% 210At. The production rate for the external target was 0.15 mCi +/- 0.056 microA(-1) h(-1) (n = 9) (5.55 MBq mcroA[-1] h[-1]). The production rate for the internal target was 0.44 +/- 0.14 mCi microA(-1) h(-1) (n = 16) (16.28 MBq mcroA[-1] h[-1]).Entities:
Mesh:
Substances:
Year: 1998 PMID: 9468021 DOI: 10.1016/s0969-8051(97)00165-0
Source DB: PubMed Journal: Nucl Med Biol ISSN: 0969-8051 Impact factor: 2.408